Almudena García-Ortiz

Research Institute Hospital 12 de Octubre — Spain

Medicine · Health Sciences

12h-index900citations31works4.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(17), Immune Cell Function and Interaction(13), Multiple Myeloma Research and Treatments(9), Immunotherapy and Immune Responses(6), Cancer Genomics and Diagnostics(5)

Publications31 total

GMP-compliant manufacturing of allogeneic peripheral blood CAR-NK cells for the treatment of acute myeloid leukemia
Cytotherapy·2025Open Access
Multi-Omic Profiling Reveals Epigenetic Drivers of Immunotherapy Resistance in Multiple Myeloma
2025Open Access
CRISPR/Cas9 Multi-Editing Enhances CAR NK Cells Therapeutic Potential Against Multiple Myeloma
Blood·2024· 5 citedOpen Access
Epigenetic Modifications As a Mechanism of Resistance to BCMA-Directed Immunotherapies in Multiple Myeloma: Insights from Multi-Omic Profiling
Blood·2024· 1 cited
PVR (CD155) epigenetic status mediates immunotherapy response in multiple myeloma
Leukemia·2024· 4 citedOpen Access
OA-02 Multiplex CRISPR/Cas9 Genome Editing of Cord Blood-derived CAR NK Cells to Improve Their Persistence and Antitumoral Potential Against Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2024
Abstract P22: PVR (CD155) epigenetic status mediates adoptive cell therapy and anti-TIGIT response in Multiple Myeloma
Blood Cancer Discovery·2024
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo
Science Translational Medicine·2024· 28 cited
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
Frontiers in Immunology·2024Open Access
CD155 on Multiple Myeloma Cells Is Epigenetically Regulated, Reduce Patients Survival and Compromises the Action of Novel Immunotherapies
Blood·2023
Personalized Monitoring of Circulating Tumor DNA By a Specific Signature of Trackable Mutations after Chimeric Antigen Receptor t-Cell Therapy in Non-Hodgkin B Cell Lymphoma
Blood·2023
OA-02 α-NKG2A blockade overcomes multiple myeloma resistance to BCMA and NKG2D CAR-NKAE cells
Clinical Lymphoma Myeloma & Leukemia·2023
Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
Frontiers in Immunology·2023· 1 citedOpen Access
S256: HLA-E/NKG2A CHECKPOINT DRIVES MULTIPLE MYELOMA RESISTANCE TO CAR-NK THERAPY
HemaSphere·2023· 2 citedOpen Access
P822: EPIGENETIC REGULATION OF CD155 ON MULTIPLE MYELOMA CELLS INFLUENCES ANTI-TUMOR NOVEL IMMUNOTHERAPEUTIC APPROACHES
HemaSphere·2023Open Access
Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients
Frontiers in Immunology·2023· 6 citedOpen Access
Personalized monitoring of circulating tumor DNA by a specific signature of trackable mutations after chimeric antigen receptor t‐cell therapy in non‐Hodgkin B cell lymphoma
Hematological Oncology·2023Open Access
Overcoming tumor resistance mechanisms in CAR-NK cell therapy
Frontiers in Immunology·2022· 84 citedOpen Access
P-015: Comprehensive comparison of allogenic CAR NK cells for MM treatment
Clinical Lymphoma Myeloma & Leukemia·2022
P-007: Exploring a safety switch in NKG2D and BCMA CAR NK-92MI immunotherapy
Clinical Lymphoma Myeloma & Leukemia·2021· 3 cited
page 1 of 2Next →

Frequent Co-authors

Joaquín Martínez‐López(26), Antonio Valeri(19), Paula Rı́o(13), Alejandra Leivas(12), María‐Teresa Cedena(11), Jessica Encinas(10), Eva Castellano(9), Santiago Barrio(9), Daniel J. Powell(8), Beatriz Martín-Antonio(7), Guillermo Suñé(7), Antonio Valeri(7), Elena Maroto-Martín(6), Vanesa Garrido(6), Laura Ugalde(6), Dean A. Lee(5), Yanira Ruiz‐Heredia(5), Miguel Gallardo(5), Rafael Alonso(5), Rafael Alonso Fernández(5)